Business Context and Reporting Period
This Form 6-K filing by Prana Biotechnology Limited (ASX: PBT) covers the month of November 2013. The document reports the results of the Annual General Meeting (AGM) held on November 28, 2013. Note: The metadata provided lists "Alterity Therapeutics Ltd," but the filing text explicitly identifies the registrant as Prana Biotechnology Limited.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a corporate governance report regarding shareholder voting outcomes rather than a financial statement.
Material Changes and Voting Results
All resolutions presented at the AGM were carried on a show of hands. The detailed voting statistics for the four resolutions are as follows:
- Resolution 1 (Non-binding Remuneration Report): 60,771,272 votes For; 3,667,139 votes Against; 24,431,402 votes Abstain. Total valid votes: 95,668,843.
- Resolution 2 (Re-Election of Non-Executive Director Mr. Brian Meltzer): 66,278,747 votes For; 961,039 votes Against; 4,931,510 votes Abstain. Total valid votes: 95,667,643.
- Resolution 3 (Ratification of previously issued securities - ATM): 66,941,977 votes For; 2,493,659 votes Against; 2,735,660 votes Abstain. Total valid votes: 95,667,643.
- Resolution 4 (Approval of 10% Placement Issue): 62,957,741 votes For; 6,570,599 votes Against; 2,642,956 votes Abstain. Total valid votes: 95,667,643.
The Chairman voted undirected proxies in his control in favor of all resolutions.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management outlook, specific risks, contingencies, or unusual items. The document is limited to the disclosure of AGM voting results as required by Listing rule 3.13.2 and Section 251AA(1) of the Corporations Act 2001.
Key Facts for Investor Verification
- Verify the company name discrepancy between the metadata (Alterity Therapeutics) and the filing (Prana Biotechnology).
- Confirm the successful ratification of the At-The-Market (ATM) facility and the 10% placement issue, which may impact future capital raising.
- Note the significant number of abstentions (approx. 24-25 million votes) on the Remuneration Report resolution.
- Confirm the re-election of Mr. Brian Meltzer as a Non-Executive Director.